DMAA NASDAQ
Drugs Made In America Acquisition Corp. Ordinary Shares
1W: +0.4%
1M: +1.1%
3M: +2.1%
YTD: +4.8%
1Y: +6.0%
$10.88
-0.01 (-0.09%)
Weekly Expected Move ±0.3%
$11
$11
$11
$11
$11
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$264.1M
52W Range10.26-10.9
Volume0
Avg Volume29,676
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEORoger Bendelac
Employees2
SectorFinancial Services
IndustryShell Companies
IPO Date2025-01-27
Websitedmaacorp.com
420 Lexington Avenue
New York, NY 10170
US
New York, NY 10170
US
(954) 870-3099
About Drugs Made In America Acquisition Corp. Ordinary Shares
Drugs Made In America Acquisition Corp. does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combinations with one or more businesses. Drugs Made In America Acquisition Corp. was incorporated in 2024 and is based in New York, New York.
Latest News
Catalyst Watch: Trump-Xi in DC, Meta Connect, and McDonald's Investor Day
Boothbay Fund Management LLC Sells 70,000 Shares of Drugs Made In America Acquisition Corp. $DMAA
Drugs Made In America Acquisition Corp. $DMAA Shares Sold by DLD Asset Management LP
Drugs Made In America Acquisition Corp. $DMAA Stock Position Reduced by ATW Spac Management LLC
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Stockwell Lynn | P-Purchase | 30,000 | — | 2025-02-18 |
| Drugs Made In Americ | P-Purchase | 400,000 | — | 2025-01-29 |